PYRGF vs. DBVT, CADL, NGNE, SLRN, IMMP, ACB, DSGN, CGC, CMPS, and YMAB
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include DBV Technologies (DBVT), Candel Therapeutics (CADL), Neurogene (NGNE), Acelyrin (SLRN), Prima BioMed (IMMP), Aurora Cannabis (ACB), Design Therapeutics (DSGN), Canopy Growth (CGC), COMPASS Pathways (CMPS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs. Its Competitors
DBV Technologies (NASDAQ:DBVT) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.
In the previous week, DBV Technologies had 4 more articles in the media than PyroGenesis Canada. MarketBeat recorded 7 mentions for DBV Technologies and 3 mentions for PyroGenesis Canada. DBV Technologies' average media sentiment score of 0.89 beat PyroGenesis Canada's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.
71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 1.4% of DBV Technologies shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
DBV Technologies has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
PyroGenesis Canada has a net margin of -115.14% compared to DBV Technologies' net margin of -3,249.99%. PyroGenesis Canada's return on equity of 0.00% beat DBV Technologies' return on equity.
PyroGenesis Canada has higher revenue and earnings than DBV Technologies. PyroGenesis Canada is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
DBV Technologies currently has a consensus price target of $14.75, indicating a potential upside of 27.83%. Given DBV Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe DBV Technologies is more favorable than PyroGenesis Canada.
Summary
DBV Technologies beats PyroGenesis Canada on 9 of the 17 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 7/4/2025 by MarketBeat.com Staff